human resources development. Data management responsibilities include the development of automated system applications to support and enhance program, fiscal, administrative and quality control operations, and the compilation and analysis of data on demographic and service trends that assist in monitoring and oversight responsibilities. Statistical analysis functions include the review of state and federal sampling procedures. The Office is responsible for the effective and efficient management of internal ACF automation processes and for oversight of state systems projects for ACF programs. In coordination with other Regional Office components, it monitors state systems projects and is the focal point for technical assistance to states and grantees on the development and enhancement of automated systems.

The Office represents the Regional Administrator on administrative matters and on internal and State systems matters with ACF central office, states, contractors and grantees. It alerts the Regional Administrator to problems or issues that have significant implications for functional areas under its jurisdiction.

C. The Office of Family Security is headed by an Assistant Regional Administrator who reports to the Regional Administrator and consists of: Child Support Enforcement Division; AFDC/JOBS Division; and Youth and Family Services Division.

The Office is responsible for providing centralized program, financial management and technical administration of certain ACF formula, entitlement and discretionary programs, such as Aid to Families with Dependent Children (AFDC), Child Support Enforcement, Jobs Opportunities and Basic Skills Training (JOBS), Child Welfare Services, Family Preservation and Support, Foster Care and Adoption Assistance, Child Abuse and Neglect, and Runaway and Homeless Youth. It is also responsible for managing all aspects of the AFDC quality control function.

A Financial/Grants Management Officer is located in the Office of Family Security to provide expertise in business and other non-programmatic areas of grants administration and to help ensure that grantees fulfill requirements of laws, regulations, and administrative policies.

The Office establishes regional financial management priorities; reviews cost allocation plans; and makes recommendations to the Regional Administrator to 1) approve, defer or disallow claims for federal financial participation in ACF formula and entitlement programs and 2) approve or disallow costs under ACF discretionary grant programs. As applicable, it makes recommendations on the clearance and closure of audits of state and grantee programs, paying particular attention to deficiencies that decrease the efficiency and effectiveness of ACF programs and taking steps to resolve such deficiencies.

The Office represents the Regional Administrator in dealing with ACF central office, states and grantees on all program and financial management policy matters for programs under its jurisdiction. It alerts the Regional Administrator to problems or issues that have significant implications for the programs.

D. The Office of Family Supportive Services is headed by an Assistant Regional Administrator who reports to the Regional Administrator and consists of: New Jersey and Caribbean Division; and New York State Division.

The Office is responsible for providing a centralized program, financial management and technical administration of certain ACF formula, entitlement, block and discretionary programs, such as Head Start, Child Care and Development Block Grant Program, Title IV-A Child Care, and Developmental Disabilities.

A Financial/Grants Management Officer is located in the Office of Family Supportive Services to provide expertise in business and other non-programmatic areas of grants administration and to help ensure that grantees fulfill requirements of laws, regulations, and administrative policies.

The Office establishes regional financial management priorities; reviews cost allocation plans; and makes recommendations to the Regional Administrator to: (1) Approve, defer or disallow claims for federal financial participation in ACF formula and entitlement programs; and (2) approve or disallow costs under ACF discretionary grant programs. As applicable, it makes recommendations on the clearance and closure of audits of state and grantee programs, paying particular attention to deficiencies that decrease the efficiency and effectiveness of ACF programs and taking steps to resolve such deficiencies.

The Office represents the Regional Administrator in dealing with ACF central office, states and grantees on all program and financial management policy matters for programs under its jurisdiction. It alerts the Regional Administrator to problems or issues that have significant implications for the programs.

Dated: April 24, 1995.

Mary Jo Bane,

Assistant Secretary for Children and Families.

[FR Doc. 95–10592 Filed 4–28–95; 8:45 am]

BILLING CODE 4184–01–P

Centers for Disease Control and Prevention

[Announcement 535]

Grant for Prevention of the Secondary Conditions Related to Autism and Pervasive Developmental Disorder; Notice of Availability of Funds for Fiscal year 1995

Introduction

The Centers for Disease Control and Prevention (CDC) announces the availability of fiscal year (FY) 1995 funds for a grant to evaluate programs to prevent secondary conditions related to autism and pervasive developmental disorder in children.

The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of ''Healthy People 2000,'' a PHS-led national activity to reduce morbidity and mortality and improve the quality of life. This announcement is related to priority area of Diabetes and Chronic Disabling Conditions. (To order a copy of ''Healthy People 2000,'' see **WHERE TO OBTAIN ADDITIONAL INFORMATION** section.)

Authority

This grant program is authorized under Section 301 and 317 (42 U.S.C. 241 and 247b) of the Public Health Service Act, as amended.

Smoke-Free Workplace

PHS strongly encourages all grant recipients to provide a smoke-free workplace and to promote the nonuse of all tobacco products, and Public Law 103–227, the Pro-Children Act of 1994, prohibits smoking in certain facilities that receive Federal funds in which education, library, day care, health care, and early childhood development services are provided to children.

Eligible Applicants

Applications may be submitted by public and private, nonprofit and for profit, organizations and governments and their agencies. Thus, universities, colleges, research institutions, hospitals, other public and private organizations, State and local governments or their bona fide agents, and small, minority- and/or women-owned businesses are eligible to apply.

Applicants must have an existing program which provides services to

children with autism and their families, and must be able to demonstrate a current caseload of at least 300 families through provision of data indicating the number of families currently receiving services.

Only one application from each eligible applicant will be accepted.

Availability of Funds

Approximately $300,000 is available in FY 1995 to fund 1 grant. It is expected that the award will begin on or about September 1, 1995, and will be made for a 12-month budget and project period. Funding estimates may vary and are subject to change.

Continuation awards within the project period will be made on the basis of satisfactory progress and the availability of funds.

Purpose

The purpose of this grant program is to:

A. Develop and evaluate a comprehensive program which includes parent training and addresses the critical factor of familial stress, for the prevention of secondary conditions in children with autism.

B. Disseminate the methodology and result of the program.

C. Provide guidance to other organizations implementing similar interventions.

Program Requirements

In conducting the activities to achieve the purpose of this program, the recipient shall be responsible for the activities listed below.

1. Develop and implement a comprehensive program which includes parental training and addresses the critical factor of familial stress, to prevent secondary conditions in young children with autism.

2. Develop and implement an evaluation plan to assess the effectiveness of the program.

3. Develop training materials to support the program.

4. Disseminate the findings and materials.

Evaluation Criteria

The application will be reviewed and evaluated according to the following criteria:

1. *Understanding of the Project 20%*

Responsiveness to the objectives of the grant program, including the understanding of the purpose of the grant program.

2. *Technical Approach 30%*

Strength of the application in describing: the proposed planning process, including specific planning objectives, strategies for achieving these objectives, a proposed schedule for achieving these objectives; and the population to be served.

3. *Capability and Experience 30%*

Demonstration of capability to conduct a project of this nature, including reputation in the field and ability to demonstrate a pre-eminent position as an appropriate organization to carry out this project, and successful experience in conducting and evaluating similar projects.

4. *Staffing and Management Resources 20%*

Demonstration that proposed Project Director is knowledgeable regarding autism and the prevention of its secondary conditions, as evidenced by publications, program summaries, or other materials that document prior work, and has committed significant time to the project. Demonstration that other professional staff have appropriate training and experience in the area of autism and the prevention of secondary conditions, as evidenced by publications, program summaries, or other materials that document prior work. Demonstration of ability to provide facilities and other necessary resources.

5. *Budget* (not scored)

Extent to which the project budget is reasonable, clearly justified, and consistent with the intended use of funds.

Executive Order 12372 Review

This program is not subject to the Executive Order 12372 review.

Public Health System Reporting Requirements

This program is not subject to the Public Health System Reporting Requirements.

Catalog of Federal Domestic Assistance Number

The Catalog of Federal Domestic Assistance Number is 93.283.

Other Requirements

Human Subjects

If the proposed project involves research on human subjects, the applicant must comply with the Department of Health and Human Services Regulations, 45 CFR Part 46, regarding the protection of human subjects. Assurance must be provided to demonstrate that the project will be subject to initial and continuing review by an appropriate institutional review committee. The applicant will be responsible for providing assurance in accordance with the appropriate guidelines and forms provided in the application kit.

Application Submission and Deadline

The applicant must submit an original and five copies of the application PHS Form 398 (OMB Number 0925–0001) to Henry S. Cassell, III, Grants Management Officer, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC), 255 East Paces Ferry Road, NE., Room 300, Mailstop E–13, Atlanta, GA 30305, on or before June 15, 1995.

Deadline:

1. Applications shall be considered as meeting a deadline if they are either:

A. Received at the above address on or before the deadline date, or

B. Sent on or before the deadline date to the above address, and received in time for the review process. Applicants should request a legibly dated U.S. Postal Service postmark or obtain a legibly dated receipt from a commercial carrier or the U.S. Postal Service. Private metered postmarks shall not be acceptable as proof of timely mailings.

2. Applications which do not meet the criteria above are considered late applications and will be returned to the applicant.

Where To Obtain Additional Information

To receive additional written information call (404) 332–4561. You will be asked to leave your name, address, and phone number, and will need to refer to Announcement 535. You will receive a complete program description, information on application procedures, and application forms.

If you have questions after reviewing the contents of all documents, business management technical assistance may be obtained from Lisa G. Tamaroff, Grants Management Specialist, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC), 255 East Paces Ferry Road, NE., Room 300, Mailstop E–13, Atlanta, GA 30305, telephone (404) 842–6796. Programmatic technical assistance may be obtained from Robert J. Delaney, Division of Birth Defects and Developmental Disabilities, National Center for Environmental Health, Centers for Disease Control and Prevention (CDC), 4770 Buford Highway, Mailstop F–34, Atlanta, GA 30341, or by calling (404) 488–7150.

A copy of ''Healthy People 2000'' (Full Report, Stock No. 017–001–00474–

0) or ''Healthy People 2000'' (Summary Report, Stock No. 017–001–00473–1) referenced in the **INTRODUCTION** may be obtained through the Superintendent of Documents, Government Printing Office, Washington, DC 20402–9325, telephone (202) 512–1800.

Dated: April 24, 1995.

Joseph R. Carter,

Acting Associate Director for Management and Operations, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95–10591 Filed 4–28–95; 8:45 am]

BILLING CODE 4163–18–P

Food and Drug Administration

[Docket No. 93F–0050]

E. I. du Pont de Nemours and Co.; Withdrawal of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the withdrawal, without prejudice to future filing, of a food additive petition (FAP 3B4360) proposing that the food additive regulations be amended to provide for the safe use of perfluoroalkylethyl acrylate copolymer, produced by the copolymerization of perfluoroalkylethyl acrylate, octadecyl methacrylate, vinylidene chloride, 2-hydroxyethyl methacrylate and polyoxyethylene methacrylate, as an oil and water repellant in paper and paperboard intended for food-contact use.

FOR FURTHER INFORMATION CONTACT: Hortense S. Macon, Center for Food Safety and Applied Nutrition (HFS–216), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3086.

SUPPLEMENTARY INFORMATION: In a notice published in the **Federal Register** of March 12, 1993 (58 FR 13603), FDA announced that a food additive petition (FAP 3B4360) had been filed by E. I. Du Pont de Nemours and Co., Du Pont Chemicals, Jackson Laboratory, Chamber Works, Deepwater, NJ 08023. The petition proposed to amend the food additive regulations in *§ 176.170 Components of paper and paperboard in contact with aqueous and fatty foods* (21 CFR 176.170) to provide for the safe use of perfluoroalkylethyl acrylate copolymer, produced by the copolymerization of perfluoroalkylethyl acrylate, octadecyl methacrylate, vinylidene chloride, 2-hydroxyethyl methacrylate, and polyoxyethylene methacrylate, as an oil and water repellant in paper and paperboard intended for food-contact use. Du Pont has now withdrawn the petition without prejudice to a future filing (21 CFR 171.7).

Dated: April 11, 1995.

Alan M. Rulis,

Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 95–10645 Filed 4–28–95; 8:45 am]

BILLING CODE 4160–01–F

[FDA–225–94–3000]

Memorandum of Understanding Between the Food and Drug Administration and the National Institutes of Health

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is providing notice of a memorandum of understanding (MOU) between FDA and the National Institutes of Health (NIH). The purpose of this MOU is to establish a relationship between the Center for Drug Evaluation and Research, FDA, and the Epilepsy Branch, National Institute of Neurological Diseases and Stroke, NIH, so that joint experiments can be conducted relating to drug metabolism and drug-drug interactions.

DATES: The agreement became effective December 13, 1993.

FOR FURTHER INFORMATION CONTACT: Jerry M. Collins, Center for Drug Evaluation and Research (HFD–400), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–4750.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 20.108(c), which states that all written agreements and memoranda of understanding between FDA and others shall be published in the **Federal Register**, the agency is publishing notice of this memorandum of understanding.

Dated: April 25, 1995.

William B. Schultz,

Deputy Commissioner for Policy.

Memorandum of Understanding Between the U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Neurological Diseases and Stroke, Epilepsy Branch and the U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research

I. Purpose

The purpose of the proposed Memorandum of Understanding (MOU) is to establish a relationship between the Center for Drug Evaluation and Research (CDER), Food and Drug Administration, and the Epilepsy Branch, National Institute of Neurological Diseases and Stroke, so that joint experiments can be conducted relating to drug metabolism and drug-drug interactions.

II. Background

Drug metabolism and drug-drug interactions represent significant issues for the FDA's mission to ensure safe and effective drugs with adequate instructions for use. For both metabolism and interactions, studies in vitro can provide substantial information needed for drug development and regulation. Review and laboratory scientists in CDER have become increasingly involved in the development of the technology for testing in vitro, and its application to modern drug development and regulation.

The Antiepileptic Drug Development (ADD) Program of the National Institute of Neurological Disorders and Stroke (NINDS) was established to collaborate with the private sector and academia effective and safe drugs for the treatment of seizures in epileptic patients. The ADD Program includes preclinical pharmacodynamic and pharmacokinetic as well as clinical investigations. The Preclinical Pharmacology Section of the Epilepsy Branch is responsible for identifying potential compounds through a multistage screening program. At present, drug-drug interactions are found by chance, as new therapeutic agents proceed through the developmental process and enter clinical trials with comedicated epileptic patients. A critical need exists to establish possible drug-drug interactions prior to the initiation of clinical trials.

III. Substance of Agreement

Staff of both the FDA's Division of Clinical Pharmacology and the Preclinical Pharmacology Section, Epilepsy Branch, NINDS will collaborate in determining metabolic pathways and potential drug-drug interactions of ADD Program compounds. The basic technology for evaluating drug-drug interactions exists in the FDA's laboratory through the use of human liver slices and subcellular fractions. The division of labor for these studies are based on the expertise and equipment found in each laboratory. Analytical methods for the identification and quantification of metabolites of the experimental compounds and clinically effective antiepileptic drugs will be developed in both laboratories under a mutual agreement based on available resources. The compounds will be supplied by the Epilepsy Branch following an agreement with the pharmaceutical sponsor. All data from these studies will remain confidential as stipulated under the present NINDS ADD Program preclinical confidentiality agreement. Any information obtained or generated under this Memorandum of Understanding will not be disclosed by FDA staff to anyone outside FDA or NINDS without permission from NINDS or the pharmaceutical sponsor.